BCG vaccination appears to trigger cross-reactive SARS-CoV-2-specific T cell response

Recently, researchers from the Monash University and Monash Medical Centre, Clayton, Victoria, Australia, investigated whether peptide sensitization using BCG can produce cross-reactive T cells specific to SARS-CoV-2. Their study is published on the preprint server, medRxiv.

from News Medical Medical Research News Feed https://ift.tt/37lvyt5